I think it's worth noting that the brand name pharmaceutical industry cannot begin to compete with the prices that have been negotiated for generic drugs. The brand names, even at best, are between $500 and $800 per person per year.
The Clinton Foundation negotiated a price initially of $139 per person per year, and that price is coming down. Even if the brand names lower their prices further, they will still be higher than the generic costs. And when you're dealing with countries where people are living at less than $1 a day, obviously the generic equivalents become the dominant force.
Yes, the legislation, in its dormancy, is disappointing, but I don't think we should be deterred. We still have a very major contribution to make through this legislation to complement and supplement whatever the brand names are doing.
At the moment, the brand names are providing the second-line drugs and they're providing the pediatric drugs, but gradually the generic equivalents are emerging. And Canada could be a force on every front, not only for the fixed-dose combination first-line drugs, but for further developments if this legislation works.